eIF3a gene polymorphism and chemo-sensitivity to platinum-based drugs in ovarian cancer.
10.11817/j.issn.1672-7347.2015.06.008
- Author:
Caiyi ZHANG
1
;
Shufen ZHANG
1
;
Yingzi LIU
2
;
Yan TIAN
1
;
Xinguo LI
1
;
Yu ZHANG
1
Author Information
1. Department of Gynaecology and Obstetrics,Xiangya Hospital,Central South University, Changsha 410008, China.
2. Institute of Clinical Pharmacology, Xiangya Hospital,
Central South University, Changsha 410008, China.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
therapeutic use;
Eukaryotic Initiation Factor-3;
genetics;
Female;
Genotype;
Humans;
Mutation;
Ovarian Neoplasms;
drug therapy;
genetics;
Platinum;
therapeutic use;
Polymorphism, Genetic;
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
- From:
Journal of Central South University(Medical Sciences)
2015;40(6):617-622
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the relationship between the eukaryotic initiation factor 3a (eIF3a)polymorphisms and chemo-sensitivity to platinum-based drug in ovarian cancer.
METHODS:Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) analysis was performed to detect 57 cases of eIF3a polymorphic genotypes (rs3824830, rs77382849, rs10787899 and rs3740556) after platinum-based chemotherapy drugs up to 6 cycles in primary ovarian cancer. The association between these gene sites was analyzed.
RESULTS:There were 3 genotypes for eIF3a rs3824830, named AA, GA and GG. The frequency distribution for them was 43.86%, 36.84% and 15.79% (2 cases did not detect the genotype, 3.51%), respectively. There were 2 genotypes for eIF3a rs77382849, named CC and TC. The frequency distribution for them was 85.96% and 12.28%(1 case did not detect the genotype, 1.76%), respectively. There were 3 genotypes for eIF3a rs10787899, named GG, GA and AA, respectively. The frequency distribution for them was 26.32%, 47.36% and 26.32%, respectively. There were significant difference in different genotypes between age group and FIGO stage (P<0.05). The genotype of eIF3a rs10787899 GA was easier to resist platinum drug compared with the GG genotype and the odds ratio could be increased by 2.676 (95%CI: 0.544-13.159). The genotype of eIF3a rs10787899 AA was easier to resist platinum drug compared with the GG genotype and the odds ratio could be increased by 5.419(95%CI: 0.964-30.471). Rebalanced by age and FIGO stage, there was no significant difference (P>0.05) among these genotype groups. In all blood samples, there was only one genotype for eIF3a rs3740556, named GG.
CONCLUSION:There is no mutation genotype in eIF3a rs3740556 loci. Polymorphism in the eIF3a rs3824830, rs77382849 and rs10787899 doesn't affect the response of ovarian cancer to platinum-based chemotherapy.
